发明名称 |
Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz |
摘要 |
A pharmaceutical composition for prevention or treatment of progression of hepatic fibrosis and cirrhosis comprises 5-(2-Pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz). ACTIVITY : Hepatotropic; Cytostatic. MECHANISM OF ACTION : TGF-beta production inhibitor. A test was conducted on macrophage cells by adding oltipraz in a dose dependent manner. The results showed that oltipraz may function as an anti-fibrotic agent in hepatic kupffer cells by inhibiting TGF-beta production. The increase in TGF-beta expression was inhibited by EGTA or genistein which was an inhibitor of tyrosine kinase. The TGF-beta inhibition was 30%. This result shows that the inhibition of TGF-beta production by oltipraz may be the result of intracellular calcium regulation and changes in protein kinase activity. |
申请公布号 |
AU3776701(A) |
申请公布日期 |
2001.10.23 |
申请号 |
AU20010037767 |
申请日期 |
2001.03.02 |
申请人 |
SANG GEON KIM |
发明人 |
SANG GEON KIM;KEON WOOK KANG |
分类号 |
C07D409/04;A61K9/08;A61K9/10;A61K9/14;A61K9/20;A61K9/48;A61K31/4965;A61K31/497;A61K31/4985;A61P1/16 |
主分类号 |
C07D409/04 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|